Coagulation Factor Deficiency Market: By Deficiency Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Factor XI Deficiency, Factor XIII Deficiency, and Others), By Product Type (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Biologics, Desmopressin, and Others), By End Users (Hospitals, Clinics, Homecare, Others) and Geography

Coagulation Factor Deficiency Market was valued at USD 14.2 billion in 2022 and is poised to grow at a CAGR of 6.7% over 2023-2029. Coagulation factor deficiency is a rare condition that affects the blood’s ability to clot normally and can be caused by genetic mutations, acquired disease, or medications. Based on the treatment type, enzyme replacement therapy is anticipated to dominate the coagulation factor deficiency market share over the forecast period. According to the World Federation of Hemophilia, there were around 1,95,263 people worldwide who had been diagnosed with hemophilia and 80,302 people who had been diagnosed with von Willebrand disease in 2019. The increasing incidences of blood-related disorders and increasing awareness of the disease will act as the coagulation factor deficiency market growth driver. However, the high cost of treatment would be the lagging factor for the market. Unmet needs for bleeding disorders, the evolving healthcare infrastructure, and increasing disposable incomes will be opportunities for market expansion.

Coagulation Factor Deficiency Market Key Developments:

• In Nov 2022, The US FDA approved CSL Behring’s Hemgenix (Etranacongene Dezaparvovec), an adeno-associated virus vector-based gene therapy, for the treatment of adults with hemophilia A and B.
• In Feb 2023, Sanofi received approval of the US FDA for Efanesoctocog alfa, a high-sustained factor VIII replacement therapy, for the treatment of hemophilia A in adults.